WASHINGTON--(BUSINESS WIRE)--The Medicines for Malaria Venture (MMV) today became the first product development partnership (PDP) to contribute intellectual property to the Pool for Open Innovation against Neglected Tropical Diseases. MMV joins GlaxoSmithKline (GSK), Alnylam Pharmaceuticals, and the Massachusetts Institute of Technology (MIT) in contributing to the Pool, which is administered by BIO Ventures for Global Health (BVGH). The Pool for Open Innovation against Neglected Tropical Diseases seeks to motivate innovative and efficient drug discovery and development by opening access to intellectual property or know-how in neglected tropical disease research. MMV’s contribution of patents to the Pool, resulting from its research for new antimalarials, is an important milestone from an organization that plays a major role in leading the development of new therapeutics for this terrible disease.
